FIB-4 Index for Liver Fibrosis Assessment

Introduction to FIB-4 Index

The FIB-4 index is a validated non-invasive biomarker that effectively identifies liver fibrosis severity in chronic liver diseases, with superior diagnostic performance compared to other serum markers, particularly for excluding advanced fibrosis, as recommended by the American Association for the Study of Liver Diseases 1, 2

In Non-Alcoholic Fatty Liver Disease (NAFLD), a FIB-4 score <1.3 indicates low risk of advanced fibrosis, while a score >1.3 requires further evaluation, according to the American Gastroenterological Association 3, 4
For Viral Hepatitis C, a FIB-4 score <1.45 excludes advanced fibrosis, and a score >3.25 suggests advanced fibrosis, as stated by the Infectious Diseases Society of America 2, 5
The European Association for the Study of the Liver recommends using age-adjusted cutoffs for FIB-4, with <65 years using 1.3 as the lower cutoff and ≥65 years using 2.0 to avoid false positives in the elderly 3, 6

The American College of Gastroenterology recommends calculating FIB-4 in patients with suspected chronic liver disease and applying disease-specific cutoffs for initial screening 1, 2
For interpretation of results, a low FIB-4 score indicates advanced fibrosis is unlikely, while an indeterminate or high score requires additional testing, as suggested by the American Association for the Study of Liver Diseases 3, 4

The FIB-4 index has the advantage of being a non-invasive alternative to liver biopsy, utilizing routine laboratory tests, and having a high negative predictive value for excluding advanced fibrosis, according to the American Gastroenterological Association 1, 2
However, it has limitations, including moderate diagnostic accuracy for positive identification of advanced fibrosis and performance affected by age, acute inflammation, and limited validation in certain liver diseases, as noted by the European Association for the Study of the Liver 1, 2, 3, 6, 5

The FIB-4 index performs best when combined with other non-invasive tests, such as vibration-controlled transient elastography (VCTE), to improve diagnostic accuracy, as recommended by the American Association for the Study of Liver Diseases 3, 6

A FIB-4 score <1.3 (or <2.0 if age ≥65 years) reliably excludes advanced fibrosis and requires only repeat testing in 2-3 years, while scores >2.67 indicate high risk for advanced fibrosis and mandate hepatology referral for liver stiffness measurement or biopsy 7, 8
Patients with a FIB-4 score <1.3 or <2.0 if ≥65 years have a negative predictive value ≥90% for excluding advanced fibrosis and do not require immediate further evaluation 7, 8, 9
Repeat FIB-4 testing should occur in 2-3 years for patients with NAFLD but without type 2 diabetes or other metabolic risk factors 7, 10
For patients with prediabetes, type 2 diabetes, or two or more metabolic risk factors, re-evaluate FIB-4 after 1-2 years 10
The age-adjusted cutoff of <2.0 for patients ≥65 years is critical to avoid false positives in elderly populations 7, 10

FIB-4 is the most validated first-line noninvasive test for NAFLD, outperforming other simple serum markers like APRI 7, 11
The standard cutoffs (<1.3 and >2.67) apply, with age adjustment to <2.0 for those ≥65 years 7, 10, 8
FIB-4 correlates directly with clinical outcomes and can serve as a screening tool for secondary prevention in high-risk populations 7
FIB-4 was originally validated in hepatitis C and maintains excellent performance in this population 11

FIB-4 excels at ruling out advanced fibrosis (high negative predictive value) but has only moderate positive predictive value for confirming disease 11
The score is more accurate for distinguishing F3-F4 (advanced fibrosis) from lower stages than for detecting F2 (moderate fibrosis) 7, 8
In primary care populations, the prevalence of advanced fibrosis is 9-15% among patients with metabolic risk factors, affecting predictive values 8, 9

Patients with NAFLD, metabolic syndrome, type 2 diabetes, chronic viral hepatitis, or unexplained elevated liver enzymes should have FIB-4 calculated, which requires only age, AST, ALT, and platelet count—all routinely available laboratory values 11
A two-tier approach (FIB-4 followed by elastography for indeterminate/high scores) maximizes diagnostic accuracy while minimizing unnecessary testing 8, 9